Skip to main content
OpenTrials
Completed

NCT Number: NCT05822076

Influence of Thoracic Paravertebral Block on Cardiac Repolarization

Aim of the study is to determine the presence and direction of electrocardiographical changes of cardiac repolarization after thoracic paravertebral block, depending on block laterality.

Injection of local anaesthetic into paravertebral space (paravertebral block, PVB) temporarily impairs transmission in nerve fibers in proximity of the deposition site. In case of PVB covering the rami of upper thoracic spinal nerves, among the others thoracic sympathetic cardiac nerves are blocked, possibly affecting action potential time of heart, especially the repolarization, and the related electrocardiographic phenomena.

The risk of life-threatening polymorphic ventricular tachycardia (torsade des pointes, TdP) is associated with certain electrocardiographical symptoms, like QT interval prolongation and increased transmural repolarization dispersion (TDR). Determining the presence and direction of cardiac repolarization changes after a thoracic PVB will allow to conclude about its impact on TdP risk: protective or, contrary, arrhythmogenic.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care

Gdansk, 80-214, Poland

About this study

After obtaining written informed consent, 60 women above 18 years of age scheduled to elective breast surgery in combined regional and general anaesthesia will be enrolled to study, divided in two groups depending of the side of operation. Participants will undergo the ultrasound-guided paravertebral block with single injection of 0.5% ropivacaine (0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients) without adjuvants. Before injection (T0) and after confirmation of sufficient sensory block area covering 1st to 4th thoracic dermatomes (T1), 12-lead electrocardiogram (ECG) will be recorded using a Holter device. First examination of sensory block distribution will be performed 6 minutes after injection, with subsequent examinations if needed - every minute up to 15 minutes. No sedative premedication, general anaesthesia induction or additional medications (except of neutral saline maintaining intravenous access) will be administered until completions of ECG recording. Both T0 and T1 electrocardiogram will be preceded by rest in supine position for at least 5 minutes, without any medical procedures other than monitoring. Cases with baseline QT or corrected QT longer than 440 milliseconds (ms) will be excluded from study.

The QT interval and TDR (measured as time in milliseconds between ECG T wave peak [Tpeak] and end [Tend]) values obtained from baseline and post-blockade electrocardiograms will be statistically analyzed and compared between study groups.

The minimum sample size was calculated as 26 cases per study group, assuming a change in corrected QT of 20 milliseconds from the baseline value, with a significance level of p=0.05 and a test power of 0.9. Sample size was expanded to 30 cases per group, due to anticipated exclusions at the stage of intervention or data analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • woman above 18 years of age, legally able of giving informed consent
  • participants previously qualified for elective breast surgery due to neoplasm, with or without axillary node dissection
  • physical status corresponding to class I or II in American Society of Anaesthesiologist classification

Exclusion criteria

  • lack of consent to participation or to regional anaesthesia for planned surgery
  • bilateral operation planned
  • symptomatic circulatory disease at the time of qualification, artificial heart pacemaker presence, positive history of arrythmia
  • allergy to amide local anaesthetics
  • use of medications with "known" or "possible" potential of QT prolongation, according to Arizona Center for Education and Research on Therapeutics [AZCERT] Inc. list, in 5 days preceding the intervention
  • severe deformation of thoracic spine

Treatment and study plan

Paravertebral block (ropivacaine) left

Procedure

Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients

Paravertebral block (ropivacaine) right

Procedure

Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients

Primary outcomes

  1. QT interval

    Time frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))

    difference in milliseconds of QT interval between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

  2. Corrected QT interval

    Time frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))

    difference in milliseconds of QT interval corrected [according to Bazett, Framingham, Fredericia formulas] between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

  3. Tpeak-Tend

    Time frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))

    difference in milliseconds of Tpeak-Tend time between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

Sponsors and collaborators

Lead sponsor

Medical University of Gdansk

Other

Registry information

Official study title

Evaluation of Influence of Thoracic Paravertebral Block on Cardiac Repolarization

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 20, 2023
Registry last updated
Aug 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.